Evidence Report/Technology Assessment Number 29

Use of Epoetin for Anemia in Chronic Renal Failure

File Inventory


Prepared by:


Blue Cross and Blue Shield Association Technology Evaluation Center
Carole Redding Flamm, M.D., M.P.H.
   Principal Investigator
Naomi Aronson, Ph.D.
Rhonda Bohn, Sc.D., M.P.H.
Beth Finkelstein, Ph.D., M.P.H.
Margaret Piper, Ph.D., M.P.H.
Jerome Seidenfeld, Ph.D.
Claudia J. Bonnell, B.S.N., M.L.S.
Maurice Carter
Maxine Gere, M.S.
Kathleen M. Ziegler, Pharm. D.
   Investigators


File Name		Description			Software	Version		File	Size
__________________________________________________________________________________________________________
01front.doc		Microsoft Word® Document	MS Word®	97 SR-1		39KB	7 pages
Contents: Cover, Title Page, Preface, Structured Abstract

02conts.doc		Microsoft Word® Document	MS Word®	97 SR-1		24KB	2 pages
Contents: Table of Contents

03summ.doc		Microsoft Word® Document	MS Word®	97 SR-1		85KB	12 pages
Contents: Summary: Overview; Reporting the Evidence; Methodology; Findings; 
Priorities for Future Research

04chap1.doc		Microsoft Word® Document	MS Word®	97 SR-1		70KB	11 pages
Contents: Chapter 1. Introduction: Scope and Objectives; Key Questions; Background; 
Clinical Practice Guidelines for Anemia in Chronic Renal Failure; Epoetin; 
Table 1. FDA-approved uses of epoetin alfa and dosing recommendations

05chap2.doc		Microsoft Word® Document	MS Word®	97 SR-1		65KB	10 pages
Contents: Chapter 2. Methodology: Overview; Technical Advisors; Search Strategy 
for the Identification of Articles; Determining Study Eligibility; Stages of Study Selection; 
Table 2. Reasons for study exclusion; Data Abstraction; Evaluation of Study Quality


06chap3.doc		Microsoft Word® Document	MS Word®	97 SR-1		278KB	47 pages
Contents: Chapter 3. Results and Conclusions: Overview; Part I: Adult Patients with 
Chronic Renal Failure; Table 3. Overview of study quality and relevance: Results and conclusions, 
Part I; Table 4. Overview of outcomes reported in each study: Results and conclusions, Part I; 
Figure 1. Mean Mortality Rate as a Function of the Average Hematocrit Value; 
Table 5. Summary of results for Pickett, Theberge, Brown, et al., 1999; 
Part II: Pediatric Patients with Chronic Renal Failure; Table 6. Summary of observed effect 
on blood pressure in selected studies using epoetin to raise Hct over 30 percent in pediatric 
patients; Part III: Subpopulations of Interest (With or Without Chronic Renal Failure); 
Table 7. Overview of study quality: Results and conclusions, Part III; 
Table 8. Overview of outcomes reported in each study: Results and conclusions, Part III

07chap4.doc		Microsoft Word® Document	MS Word®	97 SR-1		33KB	2 pages
Contents: Chapter 4. Future Research

08refs.doc		Microsoft Word® Document	MS Word®	97 SR-1		38KB	4 pages
Contents: References

09etbls.doc		Microsoft Word® Document	MS Word®	97 SR-1		293KB	47 pages
Contents: Acronyms and Abbreviations Used in Evidence Tables; 
Evidence Table 1. Randomized controlled clinical studies; 
Evidence Table 2. Nonrandomized controlled clinical trials; 
Evidence Table 3. Studies reporting cross-sectional analyses; 
Evidence Table 4. Mortality; 
Evidence Table 5. Quality of life; 
Evidence Table 6. Hospital utilization; 
Evidence Table 7. Use of red blood cell transfusion; 
Evidence Table 8. Cardiac health outcomes; 
Evidence Table 9. Cardiac intermediate health outcomes; 
Evidence Table 10. Exercise performance intermediate health outcomes; 
Evidence Table 11. Cognitive function intermediate health outcomes; 
Evidence Table 12. Sleep pattern intermediate health outcomes; 
Evidence Table 13. Nutritional status intermediate outcomes; 
Evidence Table 14. Treatment-related morbidity associated with normalization of hematocrit; 
Evidence Table 15. Randomized controlled clinical studies; 
Evidence Table 16. Studies reporting cross-sectional analyses; 
Evidence Table 17. Studies addressing impact of cardiovascular disease on relationship 
between hematocrit and outcomes; 
Evidence Table 18. Studies addressing impact of cerebrovascular disease on relationship 
between hematocrit and outcomes

10biblio.doc		Microsoft Word® Document	MS Word®	97 SR-1		328KB	51 pages
Contents: Bibliography

11appa.doc		Microsoft Word® Document	MS Word®	97 SR-1		27KB	5 pages
Contents: Appendix A. Technical Advisory Group, External Reviewers, and Medical Advisory Panel

12appb.doc		Microsoft Word® Document	MS Word®	97 SR-1		24KB	2 pages
Contents: Appendix B. Data Abstraction Forms: Renal

13appc.doc		Microsoft Word® Document	MS Word®	97 SR-1		22KB	1 page
Contents: Appendix C. Acronyms and Abbreviations
__________________________________________________________________________________________________________

AHRQ Publication No. 01-E060
Current as of June 2001


Internet Citation:

Use of Epoetin for Anemia in Chronic Renal Failure. File Inventory, Evidence Report/Technology Assessment Number 29. AHRQ Publication No. 01-E016, June 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcrfinv.htm


Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services